Article Text

Download PDFPDF

2022-RA-1623-ESGO Effect of bevacizumab and complete cytoreductive surgery in advanced low grade serous ovarian cancer: a secondary analysis of MITO 22
  1. Lucia Musacchio1,
  2. Margherita Turinetto2,
  3. Michele Bartoletti3,
  4. Laura Arenare4,
  5. Daniela Califano5,
  6. Valentina Tuninetti6,
  7. Gennaro Cormio7,
  8. Carmela Pisano8,
  9. Giorgio Valabrega9,
  10. Claudia Marchetti1,
  11. Sabrina Chiara Cecere8,
  12. Stefano Greggi10,
  13. Francesco Raspagliesi11,
  14. Francesco Perrone4,
  15. Anna Fagotti1,
  16. Domenica Lorusso1,
  17. Giovanni Scambia1 and
  18. Sandro Pignata8
  1. 1Fondazione Policlinico Universitario A. Gemelli, Rome, Italy
  2. 2University of Torino at Ordine Mauriziano, Torino, Italy
  3. 3Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy
  4. 4Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS – Fondazione G. Pascale, Naples, Italy
  5. 5Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori, IRCCS – Fondazione G. Pascale, Naples, Italy
  6. 6Department of Oncology, University of Torino at Ordine Mauriziano Hospital, Turin, Italy
  7. 7Gynecologic Oncology Istituto Tumori Giovanni Paolo II – IRCCS, Bari, Italy
  8. 8Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy
  9. 9Department of Oncology, University of Torino at Ordine Mauriziano, Torino, Italy
  10. 10Gynecologic Oncology Unit, Istituto Nazionale Tumori, IRCCS – Fondazione G. Pascale, Naples, Italy
  11. 11Gynecologic Oncology Unit, Fondazione IRCCS, Istituto Nazionale Tumori, IRCCS, Milan, Italy, Milan, Italy


Introduction/Background The aim of the present analysis was to explore the efficacy of Bevacizumab (Bev) on survival outcome in advanced low grade serous ovarian cancer (LGSOC) both in first line and in recurrent setting.

Methodology In this multicenter retrospective case control study, we compared LGSOC patients treated with chemotherapy (CT) with or without Bev, enrolled in MITO22 study. Patients receiving Bev in first-line or recurrence were considered and matched with patients receiving only CT (stage III and IV in first line; platinum based-CT in second line). Descriptive and survival analyses were performed for each group. Furthermore, the effect of upfront complete cytoreduction on progression free survival (PFS) was assessed.

Results Out of 128 patients included in MITO 22, 46 LGSOC patients receiving Bev in first-line setting or at the time of first recurrence were identified.In first line, 30 patients received Bev+CT and 65 CT alone. Median PFS were 47.86 months (95% CI: 31.48 -NR) and 22.63 months (95% CI 15 -39.24), respectively. This data was statistically significant at univariate analysis while it wasn’t at the multivariate analyses where RT was considered. Median PFS was not reached (95% CI 31.5-not reached) in patients achieving complete cytoreduction and receiving Bev, while it was 32.4 months (95% CI: 7.9–37.4) in patients with RT.In the recurrent setting, 16 patients received Bev+CT and 33 women platinum-based CT alone at the time of relapse.PFS were 37.1 months (95 CI: 13.42–40.56) and 11.22 months (95% CI: 8.26–15.63), respectively, being statistically significant (p value 0.013); no multivariate analysis were performed due to the low number of patients receiving secondary cytoreduction.

Conclusion Our study suggests that Bev might be effective in LGSOC both at diagnosis and at the time of relapse. The role of optimal cytoreduction is also confirmed. This data warrants further studies.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.